Industry news

  • 26 April 2017

    Growth of Japanese Pharma Market Driven by Biologics and Generic Drugs, Says CPhI Report

    BioPharm International

    CPhI Japan, organized by UBM EMEA and UBM Asia, returned to Tokyo for its 16th edition on April 19–21, 2017. New research into the Japanese pharmaceutical market was released at the show. More than 90 domestic and international companies who attended the event were surveyed to gauge growth opportunities in Japan. Domestic companies have projected a 17% growth in 2017, citing renewed buoyancy in the Japanese pharmaceutical economy following several years of limited growth.

  • 25 April 2017

    The top 15 spenders in the global drug R&D business: 2017

    John Carroll / Endpoints News

    You usually don’t see much annual fluctuation in the overall R&D budgets of the top 15 companies. The trend over the last few years has been to keep the lid on spending, particularly among the giants in Big Pharma. Companies didn’t cut much overall, but there was plenty of realignment going on as the industry refocused pipelines and continued a migration to the big hubs.

  • 25 April 2017

    Foreign investments in the Russian pharmaceutical industry exceeded 1 billion euros

    GMP News

    Dmitry Kurochkin, Vice-President of the Chamber of Commerce and Industry of the Russian Federation, said that, over the past few years, the Russian pharmaceutical industry showed a steady growth and is a leader compared to the other industries. The year-over-year growth consistently remains above 10%. For example, in 2016, the pharmaceutical industry grew by almost 24%. For 2016, the output of medicinal products reached 285.87 billion rubles. 77% of vital and essential drugs are already produced in Russia.

  • 24 April 2017

    Partnering to fund clinical trials: A new model for pharma

    Ben van der Schaaf / Europian Pharmaceutical Review

    The US Department of Health and Human Services estimates suggest the cost of the clinical trial process today is upwards of $100 million, and that does not even take into account the marketing and distribution investment necessary for a pharmaceutical company to ensure new life enhancing therapies reach patients’ hands. The rising costs of drug development mean that despite building a robust pipeline of early stage compounds and indications, drug makers with robust R&D pipelines are losing billions each year in potential revenue as promising new therapies sit on the shelf waiting for their patent to expire.

  • 24 April 2017

    EMA relocation's possible impact on safety monitoring 'alarming,' EU R&D chiefs say

    Phil Talor / Fierce Biotech

    As the saga of the EMA's location after Brexit rumbles on, European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the regulator.

  • 20 April 2017

    EU crushes U.K. hopes of retaining EMA after Brexit

    Nick Paul Taylor / FierceBiotech

    The European Commission has again sought to extinguish the United Kingdom’s lingering hopes of keeping the European Medicines Agency (EMA) in London after Brexit. Lead Brexiteer David Davis became the latest politician to claim London could retain the regulator earlier this week, only for a spokesperson for the commission to rubbish the idea.

  • 20 April 2017

    Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema

    Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema

    Clearside Biomedical, Inc.  (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of enrollment of an exploratory clinical trial (the “HULK” trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, with or without intravitreal Eylea® (aflibercept), for the treatment of diabetic macular edema (“DME”).

  • 17 April 2017

    The New England Journal of Medicine compared FDA and EMA

    GMP News

    The New England Journal of Medicine compared review times for new therapeutic agents that were approved by the The Food and Drug Administration (FDA) or The European Medicines Agency (EMA) between 2011 and 2015.

  • 17 April 2017

    New tuberculosis drug with proven efficacy tested in Russia

    Marchmont Innovation News

    Infectex, a Russian biomed company, has completed clinical trials for its SQ109 candidate “unparalleled elsewhere in the world,” as the developers say, the Skolkovo Foundation website  reported . Infectex claims this is the first new proven drug for tuberculosis in the global market in four decades. 

  • 14 April 2017

    China to tighten rules against faking clinical trial data, criminal charges possible

    Angus Liu / Fierce Pharma

    Forged clinical trial data have hurt China’s reputation, and the country’s administrative and judicial branches are proposing new actions against such activities in a seemingly synchronized move, and criminal charges are on the table.

All Partners

All Portfolio


  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news